Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.7751 USD 4.98% Market Closed
Market Cap: 144.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-29%
Revenue
Forecast
+8%
Operating Income
Forecast
-6%
Net Income
Forecast
+6%

Wall Street
Price Targets

NKTR Price Targets Summary
Nektar Therapeutics

Wall Street analysts forecast NKTR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NKTR is 4.845 USD with a low forecast of 1.01 USD and a high forecast of 7.35 USD.

NKTR Lowest Forecast
Wall Street Target
1.01 USD
30% Upside
NKTR Average Forecast
Wall Street Target
4.845 USD
525% Upside
NKTR Highest Forecast
Wall Street Target
7.35 USD
848% Upside
Lowest
Price Target
1.01 USD
30% Upside
Average
Price Target
4.845 USD
525% Upside
Highest
Price Target
7.35 USD
848% Upside
Nektar Therapeutics Competitors:
Price Targets
KLBF
Kalbe Farma Tbk PT
35% Upside
IOLCP
IOL Chemicals and Pharmaceuticals Ltd
34% Upside
4506
Sumitomo Pharma Co Ltd
1% Downside
C
6919
Caliway Biopharmaceuticals Co Ltd
73% Upside
KLBF
Kalbe Farma Tbk PT
35% Upside
IOLCP
IOL Chemicals and Pharmaceuticals Ltd
34% Upside
4506
Sumitomo Pharma Co Ltd
1% Downside
C
6919
Caliway Biopharmaceuticals Co Ltd
73% Upside
OCUL
Ocular Therapeutix Inc
131% Upside
SNT
Syntara Ltd
249% Upside

Revenue
Forecast

Revenue Estimate
Nektar Therapeutics

For the last 8 years the compound annual growth rate for Nektar Therapeutics's revenue is -6%. The projected CAGR for the next 3 years is -11%.

-6%
Past Growth
-11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Nektar Therapeutics

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Nektar Therapeutics

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

See Also

Summary
NKTR intrinsic value, competitors valuation, and company profile.
DCF Valuation
NKTR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NKTR stock valuation using valuation multiples.
Wall Street Estimates
NKTR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NKTR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NKTR's stock price target?
Price Target
4.845 USD

According to Wall Street analysts, the average 1-year price target for NKTR is 4.845 USD with a low forecast of 1.01 USD and a high forecast of 7.35 USD.

What is Nektar Therapeutics's Revenue forecast?
Projected CAGR
-11%

For the last 8 years the compound annual growth rate for Nektar Therapeutics's revenue is -6%. The projected CAGR for the next 3 years is -11%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.